Considering that a significant number of ER+ breast tumors initially respond to tamoxifen therapy but eventually develop resistance through various mechanism [32,33], including the overexpression of cyclin D1 [34,35,36], our findings carry significant clinical relevance. This evidence concerns the gene ESR1 and breast neoplasm.